Spots Global Cancer Trial Database for gastroenteropancreatic neuroendocrine tumor
Every month we try and update this database with for gastroenteropancreatic neuroendocrine tumor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) | NCT03017690 | Gastroenteropan... | 18 Years - | Ipsen | ||
| 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs | NCT04915144 | Neuroendocrine ... Carcinoid Tumor Pulmonary Carci... Gastroenteropan... Vipoma Insulinoma Gastrinoma | 177Lu-DOTATOC | 19 Years - | British Columbia Cancer Agency | |
| Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort | NCT06256705 | Gastroenteropan... Radiotherapy | Simultaneous 68... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor | NCT01994213 | Gastroenteropan... | Famitinib | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | NCT02611024 | Advanced Solid ... Glioblastoma Soft Tissue Sar... Endometrial Car... Epithelial Ovar... Mesothelioma Gastroenteropan... SCLC Gastric Carcino... Pancreatic Aden... Colorectal Carc... Neuroendocrine ... | Lurbinectedin Irinotecan | 18 Years - | PharmaMar | |
| Neuroendocrine Tumors - Patient Reported Outcomes | NCT05064150 | Neuroendocrine ... Gastroenteropan... Lung Neuroendoc... Neuroendocrine ... | 18 Years - | University of Iowa | ||
| Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) | NCT03017690 | Gastroenteropan... | 18 Years - | Ipsen | ||
| Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients | NCT05701241 | Gastroenteropan... | Somatostatin an... | 18 Years - | University Hospital, Antwerp | |
| Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | NCT05477576 | GEP-NET Gastroenteropan... Gastroenteropan... Neuroendocrine ... Carcinoid Carcinoid Tumor Pancreatic NET | RYZ101 Everolimus 10 m... Sunitinib 37.5 ... Octreotide LAR ... Lanreotide 120M... | 18 Years - | RayzeBio, Inc. | |
| Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. | NCT03980925 | Neuroendocrine ... Neuroendocrine ... Gastroenteropan... | Nivolumab Carboplatin Etoposide | 18 Years - | Grupo Espanol de Tumores Neuroendocrinos | |
| Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors | NCT02948946 | Gastroenteropan... Lung Neuroendoc... | NETest | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Nutrition in Gastroenteropancreatic Neuroendocrine Tumor | NCT04986085 | Gastroenteropan... | 18 Years - 80 Years | Grupo Espanol de Tumores Neuroendocrinos | ||
| Neuroendocrine Tumors - Patient Reported Outcomes | NCT05064150 | Neuroendocrine ... Gastroenteropan... Lung Neuroendoc... Neuroendocrine ... | 18 Years - | University of Iowa | ||
| 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs | NCT04915144 | Neuroendocrine ... Carcinoid Tumor Pulmonary Carci... Gastroenteropan... Vipoma Insulinoma Gastrinoma | 177Lu-DOTATOC | 19 Years - | British Columbia Cancer Agency | |
| A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor | NCT01994213 | Gastroenteropan... | Famitinib | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
